Press Releases

Press Releases

Date Title & Summary Additional Formats
09/12/18
Cidara Therapeutics to Present Data on Lead Antifungal Rezafungin at IDWeek 2018
Presentations will highlight data demonstrating the broad clinical utility, safety and potency of rezafungin to fight invasive fungal infections SAN DIEGO --(BUSINESS WIRE)--Sep. 12, 2018-- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including
09/04/18
Cidara Therapeutics to Present New Cloudbreak Data at the ESCMID/ASM Conference and 16th Annual Discovery on Target Meeting
Data highlight potential of Cloudbreak immunotherapy candidates for the treatment of multi-drug resistant Gram-negative bacterial infections SAN DIEGO --(BUSINESS WIRE)--Sep. 4, 2018-- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including
08/08/18
Cidara Provides Corporate Update and Reports Second Quarter 2018 Financial Results
SAN DIEGO , Aug. 08, 2018 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today reported financial results for the three months ended June 30, 2018 and provided an update on its corporate activities
06/15/18
Cidara Therapeutics Announces Oral Presentations on Rezafungin at Two Upcoming Global Conferences
Data Will Highlight Potential Advantages of Rezafungin for the Treatment and Prevention of Invasive Fungal Infections SAN DIEGO --(BUSINESS WIRE)--Jun. 15, 2018-- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today
05/23/18
Data to be Presented at ASM Microbe 2018 Demonstrate the Efficacy and Safety of Cidara’s Rezafungin for the Treatment of Invasive Fungal Infections
Four accepted presentations include a late-breaker featuring Phase 2 STRIVE trial data and three posters describing the activity of rezafungin against fungal pathogens SAN DIEGO --(BUSINESS WIRE)--May 23, 2018-- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel
05/21/18
Cidara Therapeutics and Rutgers University Awarded $5.5 Million Grant from NIH to Support Development of Novel Immunotherapy Agents Targeting Multi-drug Resistant Gram-negative Bacterial Infections
New Partnership to Jointly Conduct Preclinical Development of Cidara’s Cloudbreak Antibody-Drug Conjugates SAN DIEGO --(BUSINESS WIRE)--May 21, 2018-- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that
05/21/18
Cidara Therapeutics Announces Offering of Common Stock and Warrants
SAN DIEGO , May 21, 2018 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that it has entered into a securities purchase agreement with certain investors providing for the purchase and
05/10/18
Cidara Provides Corporate Update and Reports First Quarter 2018 Financial Results
SAN DIEGO , May 10, 2018 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today reported financial results for the three months ended March 31, 2018 and provided an update on its corporate activities and
04/04/18
Cidara Therapeutics to Present Rezafungin Data at the European Congress of Clinical Microbiology and Infectious Diseases 2018 Meeting
Company secures four oral presentations, including three that will highlight new data demonstrating activity of rezafungin against Candida auris and azole-resistant Aspergillus SAN DIEGO --(BUSINESS WIRE)--Apr. 4, 2018-- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing
03/21/18
Cidara Therapeutics Provides Clinical Data Updates for its Lead Antifungal Rezafungin
Additional data and analyses from  STRIVE Phase 2 clinical trial confirm positive efficacy results in both rezafungin arms Definitive Phase 1 QT clinical trial showed no cardiac abnormalities SAN DIEGO , March 21, 2018 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc.